An anticancer strategic dilemma: To kill or to contain. The choice of the pharmaceutical industry in 2009

Fundamental and Clinical Pharmacology

Volumn 25, Issue 3, 2011, Pages 283-295

  Perret, Gérard Yves ^a   Uzzan, Bernard ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Drug mechanisms of action; NCI database; Pharmaceutical industry; Pharmacology; Phases 1 and 2 trials

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 3' ETHYNYLCYTIDINE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ABT 828; AEG 40826; AEZS 112; AGS 8M14; ALB 109564; ALT 801; AMG 386; AMG 479; AMG 888; ANA 773; APO 010; AR 67; ARQ 621; ARRY 380; ARRY 520; AS 1411; AT 13387; AT 7519; AUN 944; AUY 922; AV 299; AV 412; AVE 1642; AZD 4769; AZD 7762; AZD 8055; AZD 8330; AZD 8931; BC 819; BGC 9331; BI 811283; BIIB 021; BIIB 022; BIIB 028; BIIB021; BIIB022; BMS 663513; BMS 754807; BMS 844203; BQS 481; CADI 05; CANERTINIB; CBP 501; CDX 1307; CEP 11981; CEVIPABULIN; CG 0070; CHR 3996; CIXUTUMUMAB; CNT 0888; CNT 095; CNTO 888; CONATUMUMAB; CP 870893; CRS 207; CT 332; CYC 682; CYT 107; CYT 500; DALOTUZUMAB; DENIBULIN; DIFLOMOTECAN; DINACICLIB; DULANERMIN; E 6201; E 7080; EC 0489; EGEN 001; EHC 18; ENTINOSTAT; EPETIRIMOD; EPIDERMAL GROWTH FACTOR RECEPTOR; EZN 2968; FP 1039; FRESOLIMUMAB; GSK 1059615; GSK 1120212; GSK 461364; GSK 923295; HGS 1029; IMC 18F1; IMC 3G3; IMO 2055; INCB 18424; INGN 241; INGN 401; INTETUMUMAB; IPI 493; IPILIMUMAB; ISPINESIB; JNJ 26481585; JX 594; KOS 593; KRX 0402; LE SN38; LEXATUMUMAB; LOR 2040; LP 261; LY 2181308; LY 2275796; LY 2603618; MDX 1105; MDX 1106; MDX 1307; MDX 1411; MEDI 573; MEDI 575; MK 0731; MK 1775; MK 2206; MK 5108; MK 646; MLN 8237; MM 111; MM 121; MMM 111; MOCETINOSTAT; MPC 2130; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; NB 1011; NV 1020; OBATOCLAX; OBP 301; OGX 427; OMBRABULIN; OMP21M18; ONO 1910; ONO 4538; OSI 027; OSI 906; PANOBINOSTAT; PCI 24781; PDL 192; PELITINIB; PERIFOSINE; PF 0047736; PF 03446962; PF 03732010; PF 299804; PF 3814735; PF 4856882; PLINABULIN; PLX 4032; PM 00104; PRLX 93936; PTC 299; PV 10; PV 701; R 1507; R 547; R 7167; R 7334; R 7347; R 763; RAV 12; RDEA 119; REOLYSIN; RILOTUMUMAB; RO 4987655; RO 5126766; RO 5983945; ROSCOVITINE; RP 101; RX 0201; SB 939; SCATTER FACTOR RECEPTOR; SCH 721015; SCH 900105; SCH 900776; SGT 53; SIBROTUZUMAB; SILTUXIMAB; SIMOTAXEL; SNS 314; SNX 5422; SOMATOMEDIN RECEPTOR; SPI 1620; SSR 97225; STA 9090; TAK 285; TAK 701; TAS 102; TAS 109; TB 403; TED 5710; TIGATUZUMAB; TIVOZANIB; TRC 093; TRC 102; TRC 105; TUBULIN; TUCOTUZUMAB CELMOLEUKIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARLITINIB; VASCULOTROPIN RECEPTOR; VOLASERTIB; VOLOCIXIMAB; VORELOXIN; VP 101; VQD 001; VQD 002; VTX 2337; VX 689; W G 250; XL 147; XL 281; XL 518; XL 765; XL 888; YMB 2002; Z 10201; Z10 101;

CANCER CELL; CELL KILLING; DRUG INDUSTRY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DECISION MAKING; DRUG INDUSTRY; HUMANS; NEOPLASMS;

EID: 79954478975     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00849.x     Document Type: Review

References (43)

1. Raguz S., Yague E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br. J. Cancer (2008) 99 387-391.
2. Herbst R.S. Role of novel targeted therapies in the clinic. Br. J. Cancer (2005) 92 S21-S27.
3. Hait W.N. Targeted cancer therapeutics. Cancer Res. (2009) 69 1263-1267.
4. Folkman J. Tumor angiogenesis and tissue factor. Nat. Med. (1996) 2 167-168.
5. Rubin H. Rethinking 'cancer as a dynamic developmental disorder' a quarter century later. Cancer Res. (2009) 69 2171-2175.
6. Sonnenschein C., Soto A.M. Theories of carcinogenesis: an emerging perspective. Semin. Cancer Biol. (2008) 18 372-377.
7. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer (2007) 7 834-846.
8. Uhr J.W., Scheuermann R.H., Street N.E., Vitetta E.S. Cancer dormancy: opportunities for new therapeutic approaches. Nat. Med. (1997) 3 505-509.
9. Hanahan D. A flanking attack on cancer. Nat. Med. (1998) 4 13-14.
10. Alam J.J. Apoptosis: target for novel drugs. Trends Biotechnol. (2003) 21 479-483.
11. Ralph S.J., Neuzil J. Mitochondria as targets for cancer therapy. Mol. Nutr. Food Res. (2009) 53 9-28.
12. Schimmer A.D. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. (2004) 64 7183-7190.
13. Liu P.X., Cheng H.L., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. (2009) 8 627-644.
14. Lapenna S., Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. (2009) 8 547-566.
15. Scott A.M., Cebon J. Clinical promise of tumour immunology. Lancet (1997) 349 S19-S22.
16. Kammertoens T., Schuler T., Blankenstein T. Immunotherapy: target the stroma to hit the tumor. Trends Mol. Med. (2005) 11 225-231.
17. Pardoll D.M. Cancer vaccines. Nat. Med. (1998) 4 525-531.
18. Harrison C. Rethinking therapeutic cancer vaccines. Nat. Rev. Drug Discov. (2009) 8 685-686.
19. Bradbury J. Oncolytic viral anti-cancer therapy: a magic bullet? Lancet (2001) 357 614.
20. Westphal E.M., Vonmelchner H. Gene therapy approaches for the selective killing of cancer cells. Curr. Pharm. Des. (2002) 8 1683-1694.
21. Dachs G.U., Tupper J., Tozer G.M. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs (2005) 16 349-359.
22. Rajeshkumar N., Matwyshyn G., Gulati A., Reddy G., Lenaz L. Effect of SPI-1620 on tumor perfusion and uptake of paclitaxel in a melanoma model. Mol. Cancer Ther. (2007) 6 3433S-3434S.
23. Motzer R.J., Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet (2007) 370 2071-2073.
24. Jain R.K., Tong R.T., Munn L.L. Effect of vascular normalization, by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. (2007) 67 2729-2735.
25. Tlsty T.D., Coussens L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. (2006) 1 119-150.
26. Comoglio P.M., Trusolino L. Cancer: the matrix is now in control. Nat. Med. (2005) 11 1156-1159.
27. Brigstock D.R. The connective tissue growth factor cysteine-rich 61 nephroblastoma overexpressed (CCN) family. Endocr. Rev. (1999) 20 189-206.
28. Wels J., Kaplan R.N., Rafii S., Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev. (2008) 22 559-574.
29. Wang W.G., Goswami S., Sahai E., Wyckoff J.B., Segall J.E., Condeelis J.S. Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol. (2005) 15 138-145.
30. Sabbah M., Emami S., Redeuilh G. et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist. Updat. (2008) 11 123-151.
31. Matsumoto K., Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J. Biochem. (1996) 119 591-600.
32. Matsumoto K., Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J. Cancer (2006) 119 477-483.
33. Eder J.P., Woude G.F.V., Boerner S.A., LoRusso P.M. Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer. Clin. Cancer Res. (2009) 15 2207-2214.
34. Daub H., Specht K., Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. (2004) 3 1001-1010.
35. Hassan H.T. c-Kit expression in human normal and malignant stem cells: prognostic and therapeutic implications. Leuk. Res. (2009) 33 5-10.
36. Perret G.Y., Crepin M. New pharmacological strategies against metastatic spread. Fundam. Clin. Pharmacol. (2008) 22 465-492.
37. Medina M.A., Munoz-Chapuli R., Quesada A.R. Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope. J. Cell Mol. Med. (2007) 11 374-382.
38. Hopkins A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. (2008) 4 682-690.
39. Park J.H., Kim S.H., Choi M.C. et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem. Biophys. Res. Commun. (2008) 368 318-322.
40. Zitvogel L., Kroemer G. The dilemma of anticancer therapy: tumor-specific versus immune effects. Blood (2008) 112 4364-4365.
41. Shaked Y., Kerbel R.S. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotheraphy. Cancer Res. (2007) 67 7055-7058.
42. Kerbel R.S. Therapy-induced alteration of the tumor microenvironment: impact of bone marrow derived cells. Cancer Microenviron. (2009) 2 S42.
43. Sporn M.B. The war on cancer. Lancet (1996) 347 1377-1381.